Having confirmed the presence of CD11b‐expressing macrophages (CD11b+/CD68+) in our 3D model after 14 d by flow cytometry (Figure 4a,b; Figure S8, Supporting Information), we further explored the potential of ADH‐503 treatment in modulating the tumor‐immune landscape. This evidence concerns the gene ITGAM and neoplasm.